$149 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 46 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TSHA | New | TAYSHA GENE THERAPIES INC | $12,096,246 | – | 3,827,926 | +100.0% | 8.11% | – |
New | RAYZEBIO INC | $7,649,476 | – | 344,571 | +100.0% | 5.13% | – | |
SRPT | New | SAREPTA THERAPEUTICS INCcall | $7,580,650 | – | 550 | +100.0% | 5.08% | – |
CRNX | New | CRINETICS PHARMACEUTICALS INC | $2,795,560 | – | 94,000 | +100.0% | 1.87% | – |
REPL | New | REPLIMUNE GROUP INC | $2,566,500 | – | 150,000 | +100.0% | 1.72% | – |
CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,092,068 | – | 323,349 | +100.0% | 1.40% | – |
SRPT | New | SAREPTA THERAPEUTICS INC | $1,878,910 | – | 15,500 | +100.0% | 1.26% | – |
REPL | New | REPLIMUNE GROUP INCcall | $1,766,000 | – | 1,000 | +100.0% | 1.18% | – |
ETNB | New | 89BIO INCcall | $1,523,000 | – | 1,000 | +100.0% | 1.02% | – |
BCLI | New | BRAINSTORM CELL THERAPEUTICSput | $825,000 | – | 2,500 | +100.0% | 0.55% | – |
IONS | New | IONIS PHARMACEUTICALS INC | $512,568 | – | 11,300 | +100.0% | 0.34% | – |
ETNB | New | 89BIO INC | $506,432 | – | 32,800 | +100.0% | 0.34% | – |
New | LEAP THERAPEUTICS INC | $488,749 | – | 354,166 | +100.0% | 0.33% | – | |
New | CELLECTAR BIOSCIENCES INC. | $320,232 | – | 121,300 | +100.0% | 0.22% | – | |
New | STRUCTURE THERAPEUTICS INCsponsored ads | $252,100 | – | 5,000 | +100.0% | 0.17% | – | |
New | AN2 THERAPEUTICS INC | $213,864 | – | 13,300 | +100.0% | 0.14% | – | |
New | MARINUS PHARMECEUTICALS INC | $156,975 | – | 19,500 | +100.0% | 0.10% | – | |
MRSN | New | MERSANA THERAPEUTICS INC | $126,501 | – | 99,607 | +100.0% | 0.08% | – |
GLYC | New | GLYCOMIMETIC INC | $41,250 | – | 27,500 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.